EMMA International Consulting Group, Inc. and Thema srl Announce Strategic Partnership

This Strategic Partnership will enable EMMA International and Thema to Increase Their Geographical Offerings for the Medical Device Industry

EMMA International Consulting Group, Inc. (EMMA International) a global leader in quality, regulatory, and compliance services for the Biotechnology, Pharmaceuticals, and Medical Device industries, has entered into a strategic partnership with THEMA, an Italian based strategic-regulatory consulting company focused on medical and IVD devices.

The goal of this strategic partnership is to expand geographical offerings to companies operating in the life sciences regulated space.

“At EMMA International, we are thrilled to enter into this strategic partnership with THEMA to expand our service offerings in the EU market. This strategic partnership will expand resource offerings to our clients. Together, EMMA International and THEMA bring a wealth of knowledge in regulatory affairs, quality management and product development to the medical device industry,” stated Kira Jabri, COO.

“Through this partnership we can support Manufacturers expand in the target markets by analyzing their needs, being of help in solving their issues and providing them with the most accurate service within the US and the EU landscape, whether it means providing Local Representative or auditing services or through regulatory strategic support. EMMA International has been able to reach this goal and I believe their staff has put together something we can all rely on. Thanks to them we can now help our Clients face the QA/RA challenges in the US market more confidently.” stated Marisa Testa, CEO of Thema.

Through this strategic partnership, EMMA International and Thema will be able to expand their network and capabilities to support manufacturers around the globe.

SourceThema srl

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”